Product image of Lignox Spray (Lidocaine) supplied by GNH India

Lignox Spray

Active Ingredient:
Lidocaine
Origin:
EU

Lignox Spray (Lidocaine)

Lidocaine, the active ingredient in Lignox Spray, is a local anesthetic presented as a spray for cutaneous or oromucosal use. It provides temporary numbing of surface tissues and is used to relieve pain associated with minor skin injuries, oral lesions, and minor procedural preparations.

GNH India supplies Lignox Spray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Chema Elektromet Spoldzielnia Pracy

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lignox Spray contains lidocaine, a local anesthetic that acts on peripheral nerve sodium channels to provide surface analgesia.
  • Minor skin abrasions, burns, or insect bites: provides temporary numbing and reduces pain during daily activities.
  • Aphthous ulcers and other oral mucosal lesions: eases discomfort and facilitates eating or speaking.
  • Pre‑procedural topical anesthesia for minor dermatologic or dental procedures: numbs the targeted area to improve patient tolerance.

How It Works

  • Lidocaine reversibly blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of nerve impulses. By stabilizing the neuronal membrane, it inhibits depolarization and reduces the transmission of pain signals from the peripheral site to the central nervous system, resulting in localized loss of sensation.

Side Effects

Lignox Spray may cause local or systemic adverse reactions, most of which are mild and transient.

Common Side Effects

  • Transient burning or stinging sensation at the application site
  • Mild itching or erythema of the skin or mucosa
  • Temporary tingling or numbness beyond the treated area

Serious or Rare Side Effects

  • Allergic reactions such as angioedema, urticaria, or anaphylaxis
  • Systemic toxicity presenting as dizziness, seizures, or cardiac arrhythmias
  • Rare methemoglobinemia, especially with extensive mucosal use

Precautions & Warnings

  • When using Lignox Spray, consider the following safety measures.
  • Allergy assessment: avoid if known hypersensitivity to lidocaine or other amide‑type anesthetics.
  • Application area: limit to intact skin or mucosa; do not apply to open wounds or heavily damaged tissue.
  • Dosage limit: do not exceed the total recommended amount per treatment session as advised by the prescriber.
  • Concurrent anesthetics: avoid using multiple lidocaine‑containing products simultaneously to prevent cumulative toxicity.
  • Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Lignox Spray may interact with other medications; consider the following.

Major Interactions (Avoid)

  • Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase systemic lidocaine concentrations.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise lidocaine levels and risk toxicity.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may enhance cardiac depressant effects of lidocaine.
  • Concurrent use of other local anesthetics: increases risk of cumulative systemic toxicity.
  • Epinephrine‑containing products: may alter lidocaine absorption and prolong its action.

Frequently Asked Questions

Lignox Spray is a lidocaine‑based topical formulation used to provide temporary numbness and pain relief on the skin or oral mucosa. It is commonly applied to minor abrasions, burns, insect bites, aphthous ulcers, and before minor dermatologic or dental procedures to improve patient comfort.

Lidocaine works by reversibly blocking voltage‑gated sodium channels on peripheral nerves. This inhibition prevents the initiation and propagation of nerve impulses, thereby reducing the transmission of pain signals from the site of application to the brain and producing localized anesthesia.

The appropriate amount of Lignox Spray is determined by the prescribing healthcare professional based on the size of the area to be treated and the specific clinical situation. Patients should follow the prescriber’s instructions and not exceed the recommended total amount per session.

Safety data for lidocaine spray in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually before prescribing.

To request Lignox Spray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lignox Spray delivers lidocaine, an amide‑type local anesthetic, which offers rapid onset and reliable surface numbness. Compared with ester‑type anesthetics such as benzocaine, lidocaine generally has a lower risk of allergic reactions and provides a longer duration of action, making it suitable for a broader range of minor procedures.

Lignox Spray should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and sources of heat. Ensure the spray nozzle is clean and capped when not in use to maintain product integrity.

Lignox Spray is applied directly to the target skin or oral mucosal area as a fine mist. The prescribed amount is sprayed onto the surface, allowing it to spread evenly. The spray should be used on intact tissue, and the treated area is typically left uncovered to allow absorption.

Serious risks include systemic lidocaine toxicity, which can manifest as dizziness, seizures, or cardiac arrhythmias, and severe allergic reactions such as angioedema or anaphylaxis. Rarely, extensive mucosal use may lead to methemoglobinemia. Any signs of systemic effects or allergic response require immediate medical attention.

Individuals with a known hypersensitivity to lidocaine, other amide‑type local anesthetics, or any component of the spray formulation should avoid its use. It is also contraindicated on broken skin, heavily damaged mucosa, or in patients where the prescriber determines that the risks outweigh the benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lidocaine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT